The use of cationic liposomes to co-deliver docetaxel and siRNA for targeted therapy of hepatocellular carcinoma

doi:10.5246/jcps.2014.10.085

Abstract

Abstract:

Hepatocellular carcinoma (HCC) is one of the major causes of death worldwide. Targeted delivery of drugs to tumor cells can be achieved by introduction of a targeting ligand onto the nanocarrier system. Simultaneous delivery of a chemotherapeutic drug and siRNA in one nanocarrier system to the tumor is a promising strategy for cancer treatment. In this study, we prepared cationic liposomes to co-deliver docetaxel (DTX) and small interfering RNA (siRNA). The liposomes were modified by a hepatocellular carcinoma specific homing peptide, SP94. Serum stability assay demonstrated that liposomes can significantly protect the siRNA against enzymatic degradation in serum. The SP94 modified liposomes showed increased cellular uptake and stronger anti-tumor effect compared with the unmodified liposomes on human HCC cells. The data indicated that the SP94 modified liposomes which co-deliver DTX and siRNA could be used for the targeted therapy of hepatocellular carcinoma.

Key words: SP94, Hepatocellular carcinoma, Liposomes, Docetaxel, siRNA

CLC Number:

R943

Supporting:

Jingquan Li, Zhenzhen Yang, Tingting Meng, Xianrong Qi . The use of cationic liposomes to co-deliver docetaxel and siRNA for targeted therapy of hepatocellular carcinoma[J]. Journal of Chinese Pharmaceutical Sciences, 2014, 23(10): 667-673.

References

[1] Miyahara, K.; Nouso, K.; Yamamoto, K. World J. Gastroenterol. 2014, 20, 4151-4159.

[2] Kikuchi, L.; Oliveira, C.P.; Carrilho, F.J. Biomed. Res. Int. 2014, 2014, 106247.

[3] Chan, S.L.; Yeo, W. World J. Gastroenterol. 2014, 20, 3135-3145.

[4] Sun, T.M.; Du, J.Z.; Yao, Y.D.; Mao, C.Q.; Dou, S.; Huang, S.Y.; Zhang, P.Z.; Leong, K.W.; Song, E.W.; Wang, J. ACS Nano. 2011, 5, 1483-1494.

[5] Greco, F.; Vicent, M.J. Adv. Drug Deliv. Rev. 2009, 61, 1203-1213.

[6] Zheng, C.; Zheng, M.; Gong, P.; Deng, J.; Yi, H.; Zhang, P.; Zhang, Y.; Liu, P.; Ma, Y.; Cai, L. Biomaterials. 2013, 34, 3431-3438.

[7] Yang, Z.Z.; Li, J.Q.; Wang, Z.Z.; Dong, D.W.; Qi, X.R. Biomaterials. 2014, 35, 5226-5239.

[8] Kulhari, H.; Pooja, D.; Shrivastava, S.V.G.M.N.; Sistla, R. Colloids Surf. B. Biointerfaces. 2014, 117C, 166-173.

[9] Symmans, W.F.; Volm, M.D.; Shapiro, R.L.; Perkins, A.B.; Kim, A.Y.; Demaria, S.; Yee, H.T.; McMullen, H.; Oratz, R.; Klein, P.; Formenti, S.C.; Muggia, F. Clin. Cancer Res. 2000, 6, 4610-4617.

[10] Engels, F.K.; Mathot, R.A.; Verweij, J. Anticancer Drugs. 2007, 18, 95-103.

[11] Tan, Q.; Liu, X.; Fu, X.; Li, Q.; Dou, J.; Zhai, G. Expert. Opin. Drug Deliv. 2012, 9, 975-90.

[12] Boutros, M.; Ahringer, J. Nat. Rev. Genet. 2008, 9, 554-566.

[13] Uchino, K.; Ochiya, T.; Takeshita, F. Jpn. J. Clin. Oncol. 2013, 43, 596-607.

[14] Kanasty, R.; Dorkin, J.R.; Vegas, A. Nat. Mater. 2013, 12, 967-977.

[15] Castanotto, D.; Rossi, J.J. Nature. 2009, 457, 426-433.

[16] Lee, J.M.; Yoon, T.J.; Cho, Y.S. Biomed. Res. Int. 2013, 782041.

[17] Deng, Y.; Wang, C.C.; Choy, K.W.; Du, Q.; Chen, J.; Wang, Q.; Li, L.; Chung, T.K.; Tang, T. Gene. 2014, 538, 217-227.

[18] Ashley, C.E.; Carnes, E.C.; Phillips, G.K.; Padilla, D.; Durfee, P.N.; Brown, P.A.; Hanna, T.N.; Liu, J.; Phillips, B.; Carter, M.B.; Carroll, N.J.; Jiang, X.; Dunphy, D.R.; Willman, C.L.; Petsev, D.N.; Evans, D.G.; Parikh, A.N.; Chackerian, B.; Wharton, W.; Peabody, D.S.; Brinker, C.J. Nat. Mater. 2011, 10, 389-397.

[19] Lo, A.; Lin, C.T.; Wu, H.C. Mol. Cancer Ther. 2008, 7, 579-589.

[20] Ashley, C.E.; Carnes, E.C.; Phillips, G.K.; Durfee, P.N.; Buley, M.D.; Lino, C.A.; Padilla, D.P.; Phillips, B.; Carter, M.B.; Willman, C.L.; Brinker, C.J.; Caldeira Jdo, C.; Chackerian, B.; Wharton, W.; Peabody, D.S. ACS Nano. 2011, 5, 5729-5745.

[21] Toita, R.; Murata, M.; Abe, K.; Narahara, S.; Piao, J.S.; Kang, J.H.; Hashizume, M. Chem. Commun (Camb). 2013, 49, 7442-7444.

[22] Toita, R.; Murata, M.; Tabata, S.; Abe, K.; Narahara, S.; Piao, J.S.; Kang, J.H.; Hashizume, M. Bioconjug. Chem. 2012, 23, 1494-1501.

[23] Meng, T.T.; Li, J.Q.; Qi, X.R. J. Chin. Pharm. Sci. 2014, 23, 145-152.

[24] Xiang, B.; Dong, D.W.; Shi, N.Q.; Gao, W.; Yang, Z.Z.; Cui, Y.; Cao, D.Y.; Qi, X.R. Biomaterials. 2013, 34, 6976-6991.

[25] Li, X.; Zhang, J.; Wang, D.K.; Pan, W.S. Acta Pharm. Sin. 2012, 47, 1219-1226.

[26] Gorle, S.; Ariatti, M.; Singh, M. Eur. J. Pharm. Sci. 2014, 10.1016/j.ejps.2014.04.012.

[27] Liu, Z.; Liu, D.; Wang, L.; Zhang, J.; Zhang, N. Int. J. Mol. Sci. 2011, 12, 1684-1696.

[28] Li, Y.; Cheng, Q.; Jiang, Q.; Huang ,Y.; Liu, H.; Zhao, Y.; Cao, W.; Ma, G.; Dai, F.; Liang, X.; Liang, Z.; Zhang, X. J. Control. Release. 2014, 176, 104-114.

[29] Dong, D.W.; Xiang, B.; Gao, W.; Yang, Z.Z.; Li, J.Q.; Qi, X.R. Biomaterials. 2013, 34, 4849-4859.

[30] Bansal, D.; Yadav, K.; Pandey, V.; Ganeshpurkar, A.; Agnihotri, A.; Dubey, N. Drug Deliv. 2014, 10.3109/ 10717544.2014.907373.

[31] Sakuma, S.; Yamashita, S.; Hiwatari, K.; Hoffman, R.M.; Pham, W. Curr. Drug Discov. Technol. 2011, 8, 367-378.

[32] Buyens, K.; De Smedt, S.C.; Braeckmans, K.; Demeester, J.; Peeters, L.; van Grunsven, L.A.; de Mollerat du Jeu, X.; Sawant, R.; Torchilin, V.; Farkasova, K.; Ogris, M.; Sanders, N.N. J. Control. Release. 2012, 158, 362-370.

[33] Ozpolat, B.; Sood, A.K.; Lopez-Berestein, G. Adv. Drug Deliv. Rev. 2014, 66, 110-116.